Latest news articles

Added 8 days ago Drug news

Data from phase III UNIFI study of Stelara shows remission in ulcerative colitis

The Janssen Pharmaceutical Companies of Johnson & Johnson announced new data from the Phase III UNIFI study showing that a...

Added 9 days ago Drug news

New Phase 3 data on Stelara (ustekinumab) in Ulcerative Colitis

New Phase 3 data on Stelara® (ustekinumab) in Ulcerative Colitis was presented on Saturday at the 14th Congress of the European Crohn’s and Colitis Organisation (ECCO) in Copenhagen.

Added 10 days ago Drug news

Phase III VARSITY trial shows Entyvio superior to Humira in ulcerative colitis

Takeda Pharmaceutical announced results from the Phase IIIb head-to-head VARSITY study which demonstrated that the gut-selective biologic Entyvio (vedolizumab) was...

Search all news articles for Regional enteritis and ulcerative colitis

Learning Zones

An Learning Zone (LZ) is an area of the site dedicated to providing detailed self-directed medical education about a disease, condition or procedure.

Inflammatory Bowel Disease Knowledge Centre

Inflammatory Bowel Disease Knowledge Centre

The Inflammatory Bowel Disease (IBD) Knowledge Centre contains key information relating to the epidemiology and pathophysiology of Crohn’s disease and ulcerative colitis, highlighting prevalence, impact and unmet needs and the underlying inflammatory processes that drive IBD, considering some of the key inflammatory pathways.

Inflammatory bowel disease assessment tools

Inflammatory bowel disease assessment tools

'New IBD assessment tools at a glance' - an educational symposium sponsored by Sandoz.

Load more


Guidelines for the investigation of chronic diarrhoea in adults: British Society of Gastroenterology, 3rd edition

Chronic diarrhoea is a common problem, hence clear guidance on investigations is required. This is an updated guideline from 2003 for the investigations of chronic diarrhoea...

Added 9 months ago

ECCO-ESCP Consensus on Surgery for Crohn’s Disease

The goal of this consensus initiated by the European Crohn’s and Colitis Organisation [ECCO] and European Society of Colo-Proctology [ESCP] was to establish European consensus guidelines for the surgical treatment of Crohn’s disease [CD].

Added 8 months ago

Third European Evidence-based Consensus on Diagnosis and Management of Ulcerative Colitis. Part 2: Current Management

The guideline has been condensed into two papers,[...] the second describing current therapeutic management [treatment of active disease and maintenance of medically induced remission].

Added 8 months ago

Search all guidelines for Regional enteritis and ulcerative colitis

Journal articles

Systematic review: predictive biomarkers of therapeutic response in inflammatory bowel disease-personalised medicine in its infancy.

Aim: To systematically review the available literature on predictive biomarkers of therapeutic response in IBD.

Added 14 days ago

Fecal microbiota profiles in treatment-naïve pediatric inflammatory bowel disease - associations with disease phenotype, treatment, and outcome.

Purpose: Imbalance in the microbiota, dysbiosis, has been identified in inflammatory bowel disease (IBD). We explored the fecal microbiota in pediatric patients with treatment-naïve IBD, non-IBD patients with gastrointestinal...

Added 14 days ago

Clinical disease activity and endoscopic severity correlate poorly in children newly diagnosed with Crohn's disease.

Our aim was to compare endoscopic severity with the weighted Pediatric Crohn’s Disease Activity Index (wPCDAI) in children with newly diagnosed CD.

Added 14 days ago

Search all journal articles for Regional enteritis and ulcerative colitis

Clinical trials

The Impact of Anti-TNF Exposure on Vedolizumab Effectiveness

Vedolizumab is a new medication being used for the treatment of Crohn's disease and Ulcerative colitis. It works by blocking specific white blood cells (alpha 4-beta7 lymphocytes) from migrating to areas of inflammation in...

Added 1 year ago

A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of ABT-494 for the Induction of Symptomatic and Endoscopic Remission in Subjects With Moderately to Severely Active Crohn's Disease Who Have Inadequately Responded to or Are Intolerant to Immunomodulators or Anti-TNF Therapy

To determine the efficacy and safety of multiple doses of ABT-494 in subjects with moderately to severely active Crohn's Disease with a history of inadequate response to or intolerance to Immunomodulators or anti-Tumor Necrosis Factor...

Added 1 year ago

Personalising Anti-TNF Therapy in Crohns Disease (PANTS)

The primary objective of this study is to investigate the mechanisms that underlie primary non-response (PNR), loss of response (LOR) and adverse drug reactions (ADRs) to anti-TNF drugs in patients with active luminal Crohn's disease.

Added 1 year ago

Search all clinical trials for Regional enteritis and ulcerative colitis
Allen Wellings

UEGW 2018 | Day 5 Highlights

A number of presentations and abstracts shared updates on the latest developments for new treatments and therapies, some of which are pioneering new modes of action. Here we look to the horizon, gaining insights into the latest data for novel treatments targeting Janus kinase (JAK) signalling, MAdCAM-1-mediated adhesion and the interleukin IL-23.